![Vijay Samant](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vijay Samant
Direttore/Membro del Consiglio presso
Xiconic Pharmaceuticals LLC
Profilo
Vijay B. Samant currently works at Xiconic Pharmaceuticals LLC, as Director.
Mr. Samant also formerly worked at Vical, Inc., as President, Chief Executive Officer & Director from 2000 to 2019, AmpliPhi Biosciences Corp., as Independent Director from 2015 to 2019, Materials Management, Inc., as Executive Director, BioMarin Pharmaceutical, Inc., as Director from 2002 to 2004, Aeras Global TB Vaccine Foundation, as Director in 2010, Raptor Pharmaceuticals Corp., as Director from 2011 to 2014, Horizon Pharmaceutical LLC, as Independent Director from 2011 to 2014, Fresh Tracks Therapeutics, Inc., as Independent Director from 2000 to 2023, Merck & Co., Inc., as Chief Operating Officer-Vaccine Division from 1998 to 2000, National Foundation for Infectious Diseases, as Trustee from 2003 to 2012, and International Vaccine Institute, as Trustee from 2011 to 2012.
Mr. Samant received his graduate degree in 1977 from The Trustees of Columbia University in The City of New York, undergraduate degree in 1975 from the University of Mumbai, and Masters Business Admin degree in 1983 from MIT Sloan School of Management.
Posizioni attive di Vijay Samant
| Società | Posizione | Inizio |
|---|---|---|
Xiconic Pharmaceuticals LLC
 Xiconic Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology The private company is based in Blue Bell, PA. Xiconic Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapies targeting activated matriptase (ACTM), a tumor-specific antigen overexpressed in various epithelial cancers and certain lymphomas. Its lead product, XCN-010 (Matriptimab™-MMAE), is an antibody-drug conjugate that selectively binds ACTM on tumor cells, enabling targeted delivery of the cytotoxic agent monomethyl auristatin E (MMAE). Using proprietary pegylation technology, XCN-010 enhances linker stability, reduces off-target toxicity, and ensures efficient intracellular drug release. Preclinical studies show antitumor activity across multiple cancer types, including breast, non-small cell lung, prostate cancers, and mantle cell lymphoma, with efficacy demonstrated both in vitro and in vivo. The company’s development is based on licensed intellectual property from Rutgers and Georgetown Universities and aims to advance XCN-010 into clinical trials for multiple cancer indications. Xiconic Pharmaceuticals LLC was founded in 2016. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Vijay Samant
| Società | Posizione | Fine |
|---|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 02/10/2023 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Amministratore Delegato | 01/08/2019 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics | Direttore/Membro del Consiglio | 01/01/2019 |
| RAPTOR PHARMACEUTICAL CORP | Direttore/Membro del Consiglio | 28/07/2014 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops drugs and drug-delivery platforms | Direttore/Membro del Consiglio | 01/01/2014 |
Formazione di Vijay Samant
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
88
Relazioni di 1° grado
15
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 15 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics | Health Technology |
Materials Management, Inc.
 Materials Management, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in planning and management of precious metal assets | Commercial Services |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Mumbai
 University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops drugs and drug-delivery platforms | Health Technology |
National Foundation for Infectious Diseases
 National Foundation for Infectious Diseases Miscellaneous Commercial ServicesCommercial Services Operates voluntary health organization | Commercial Services |
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services Develops and distributes vaccines | Commercial Services |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of life-altering therapeutics that treat debilitating and often fatal diseases | Health Technology |
MIT Sloan School of Management
 MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fresh Tracks Therapeutics, Inc.
 Fresh Tracks Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates pharmaceutical company that develops and manufactures prescription therapeutics products for the treatment of autoimmune, inflammatory and debilitating diseases | Health Technology |
Xiconic Pharmaceuticals LLC
Xiconic Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology The private company is based in Blue Bell, PA. Xiconic Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapies targeting activated matriptase (ACTM), a tumor-specific antigen overexpressed in various epithelial cancers and certain lymphomas. Its lead product, XCN-010 (Matriptimab™-MMAE), is an antibody-drug conjugate that selectively binds ACTM on tumor cells, enabling targeted delivery of the cytotoxic agent monomethyl auristatin E (MMAE). Using proprietary pegylation technology, XCN-010 enhances linker stability, reduces off-target toxicity, and ensures efficient intracellular drug release. Preclinical studies show antitumor activity across multiple cancer types, including breast, non-small cell lung, prostate cancers, and mantle cell lymphoma, with efficacy demonstrated both in vitro and in vivo. The company’s development is based on licensed intellectual property from Rutgers and Georgetown Universities and aims to advance XCN-010 into clinical trials for multiple cancer indications. Xiconic Pharmaceuticals LLC was founded in 2016. | Health Technology |
